Session 8
Vaccines I

Programme

• 02:45 p.m. – 03:00 p.m. 10 Min. 5 Min.

  • Abstract Talk
  • AT 19

  Pre-existing flavivirus immunity reshapes the immunodominance and impacts the immunogenicity of the yellow fever vaccine

  • Antonio Santos Del Peral (Munich / DE)

   Vaccines
• 03:00 p.m. – 03:15 p.m. 10 Min. 5 Min.

  • Abstract Talk
  • AT 20

  The pragmatic, multi-center, three-arm, partially randomized HEVACC trial – heterologous SARS-CoV-2 vaccination with ChAdOx-1 and BNT162b2

  • Dr. Janine Kimpel (Innsbruck / AT)

   Vaccines
• 03:15 p.m. – 03:30 p.m. 10 Min. 5 Min.

  • Abstract Talk
  • AT 21

  Intranasal administration of a novel live-attenuated SARS-CoV-2 vaccine candidate induces protective immunity in vivo

  • Dr. Güliz Tuba Barut (Bern / CH)

   Vaccines
• 03:30 p.m. – 03:45 p.m. 10 Min. 5 Min.

  • Abstract Talk
  • AT 22

  Humoral immune response of mice against a chimera of glycoproteins B of bovine herpesviruses 1 and 5

  • Dr. Juan Sebastian Quintero Barbosa (Bogota / CO)

   Vaccines
• 03:45 p.m. – 04:00 p.m. 10 Min. 5 Min.

  • Abstract Talk
  • AT 23

  Measles vaccine induces CD8⁺ resident memory T cells in the lungs and the liver after a single administration

  • Heidy Vera Peralta (Paris / FR)

   Vaccines, Viral vectors
• 04:00 p.m. – 04:15 p.m. 10 Min. 5 Min.

  • Abstract Talk
  • AT 24

  Leishmania-derived virus-like particles as a potential vaccine antigen against tick-borne encephalitis virus

  • Marta Zimna (Gdansk / PL)

   Antivirals, Vaccines